Description

Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains.

FIGURE 6

Chart

Source Paper

Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and continuous Bayesian network meta-analysis.

Frontiers in medicine (2022)

PMID: 36755885

DOI: 10.3389/fmed.2022.998623

Cite This Figure

![FIGURE 6: Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900126/bin/fmed-09-998623-g006.jpg)

> Source: Peter R Feldman et al. "Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A syst." *Frontiers in medicine*, 2022. PMID: [36755885](https://pubmed.ncbi.nlm.nih.gov/36755885/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900126/bin/fmed-09-998623-g006.jpg" alt="Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains." />
  <figcaption>FIGURE 6. Risk of bias assessment across included randomized controlled trials in the AGA treatment network meta-analysis, evaluated using the Cochrane Risk of Bias tool domains.<br>  Source: Peter R Feldman et al. "Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A syst." <em>Frontiers in medicine</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36755885/">36755885</a></figcaption>
</figure>